202 related articles for article (PubMed ID: 30763469)
1. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.
Aydin V; Akici A; Isli F; Aksoy M; Aydin M; Gursoz H
J Clin Pharm Ther; 2019 Aug; 44(4):553-560. PubMed ID: 30763469
[TBL] [Abstract][Full Text] [Related]
2. Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
Chan MJ; Wen YH; Huang YB; Chuang HY; Tain YL; Lily Wang YC; Hsu CN
J Clin Pharm Ther; 2018 Apr; 43(2):256-264. PubMed ID: 29119581
[TBL] [Abstract][Full Text] [Related]
3. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
[TBL] [Abstract][Full Text] [Related]
4. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
5. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
6. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of mycobacterial infections associated with anti-rheumatic medications.
Brode SK; Jamieson FB; Ng R; Campitelli MA; Kwong JC; Paterson JM; Li P; Marchand-Austin A; Bombardier C; Marras TK
Thorax; 2015 Jul; 70(7):677-82. PubMed ID: 25911222
[TBL] [Abstract][Full Text] [Related]
8. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden.
Tam LS; Leung CC; Ying SK; Lee GK; Yim CW; Leung YY; Kun EW; Wong KK; Li EK
Clin Exp Rheumatol; 2010; 28(5):679-85. PubMed ID: 20822708
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
[TBL] [Abstract][Full Text] [Related]
10. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.
Kisacik B; Pamuk ON; Onat AM; Erer SB; Hatemi G; Ozguler Y; Pehlivan Y; Kilic L; Ertenli I; Can M; Direskeneli H; Keser G; Oksel F; Dalkilic E; Yilmaz S; Pay S; Balkarli A; Cobankara V; Cetin GY; Sayarlioglu M; Cefle A; Yazici A; Avci AB; Terzioglu E; Ozbek S; Akar S; Gul A
J Rheumatol; 2016 Mar; 43(3):524-9. PubMed ID: 26773107
[TBL] [Abstract][Full Text] [Related]
11. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
13. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Lorenzetti R; Zullo A; Ridola L; Diamanti AP; Laganà B; Gatta L; Migliore A; Armuzzi A; Hassan C; Bruzzese V
Ann Med; 2014 Nov; 46(7):547-54. PubMed ID: 25105206
[TBL] [Abstract][Full Text] [Related]
14. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
[TBL] [Abstract][Full Text] [Related]
15. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area.
Kim HW; Park JK; Yang JA; Yoon YI; Lee EY; Song YW; Kim HR; Lee EB
Clin Rheumatol; 2014 Sep; 33(9):1307-12. PubMed ID: 24057090
[TBL] [Abstract][Full Text] [Related]
17. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
18. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
[TBL] [Abstract][Full Text] [Related]
19. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
20. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
